Spotlight: Implications of Just Published New PTAB Rules
The use of inter partes review (IPR) to challenge bio/pharma patents has grown significantly — with the number nearly doubling in 2015 alone. While relatively few of them have reached final decisions, what gives some challengers the winning edge?
Please join our experienced attorneys for a discussion on the key challenges you could face with your next IPR, as well as your overall strategies for patent litigation and enforcement, and how to prepare to address them.
Topics include:
Determining trends based on the first 105+ bio/pharma IPR petitions to be filed
Discovering the most vulnerable types of bio/pharma patents
Learning how to prosecute bio/pharma patents to withstand IPR
Employing tactics to help prevent an institution decision
Understanding more about biosimilar and biologics-related IPRs
Reviewing updates on PTAB rule changes
Speakers
Stephen Maebius, Partner, IP Department, Foley & Lardner LLP
